--- title: "Pre-market hot trades in US stocks: Boston Scientific up 3.38% in pre-market; FGI Industries down 3.29% in pre-market" type: "News" locale: "en" url: "https://longbridge.com/en/news/295915797.md" description: "Boston Scientific pre-market up 3.38%; FGI Industries pre-market down 3.29%; Microbus pre-market up 174.24%; Capricor Therapeutics pre-market up 80.52%; Akanda pre-market up 62.45%" datetime: "2026-08-14T09:59:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295915797.md) - [en](https://longbridge.com/en/news/295915797.md) - [zh-HK](https://longbridge.com/zh-HK/news/295915797.md) --- # Pre-market hot trades in US stocks: Boston Scientific up 3.38% in pre-market; FGI Industries down 3.29% in pre-market **Pre-market Hot Trades in US Stocks** Boston Scientific is up 3.38% in pre-market trading. Based on recent key news: 1. On August 14, MarketBeat pointed out that although Boston Scientific received a moderate buy rating from analysts, top analysts preferred to recommend five other stocks. This information may lead investors to reassess the investment value of Boston Scientific, affecting the stock price increase. 2. On August 12, a report from MarketBeat showed that Boston Scientific was not included in the list of five stocks recommended by top analysts, despite its moderate buy rating. This may prompt investors to adopt a cautious attitude towards its future performance, affecting market sentiment. 3. On August 11, Citigroup Global Markets Funding Luxembourg S.C.A. released a series of structured products linked to a basket of stocks, which may impact market capital flows and indirectly affect Boston Scientific's stock price. Market capital flows are active, and industry dynamics should be monitored. FGI is down 3.29% in pre-market trading. Based on recent key news: 1. On August 12, FGI Industries announced its second-quarter financial report, with revenue of $31.9 million, net profit of $1.2 million, and a gross margin of 33.4%. The report showed an improvement in the company's profitability, but the market remains cautious about future growth, leading to stock price fluctuations. Source: Reuters 2. On August 13, FGI reiterated its revenue guidance for 2026 at $134 million to $141 million, exceeding market expectations. Despite uncertain market conditions, the company's strategic investments continue to drive growth, impacting the stock price. Source: Benzinga 3. On August 13, FGI's relative strength index was 54.32, with a 33.98% increase in stock price over the past year. The current stock price is near a 52-week low, indicating a cautious market attitude towards its future performance. Source: Benzinga The industry faces tariff pressures, and the market is cautious. **Top Gainers in Pre-market US Stocks** Microbus is up 174.24% in pre-market trading. Based on recent key news: 1. On August 10, Wetour Robotics Ltd. released important information through the EDGAR system, possibly involving strategic adjustments or new product launches, driving a significant increase in stock price. Source: EDGAR 2. On August 11, the market's tolerance for traditional business models has decreased, and investors' expectations for digital transformation have increased, which may affect Microbus's market positioning and investor confidence. Source: Market Analysis 3. No other significant news recently. Increased market focus on digital transformation. Capricor Therapeutics is up 80.52% in pre-market trading. Based on recent key news: 1. On August 14, Capricor Therapeutics reported a net loss of $40.7 million for the second quarter, with an adjusted loss per share of $0.70, and cash and cash equivalents decreased to $237.9 million The company's stock price fell by 82.6% in the second quarter and has decreased by 85.5% year-to-date. 2. On August 14, Capricor Therapeutics was accused of violating the blinding and protocol in the HOPE-3 trial and created a statistical analysis plan the day before data unblinding, leading to significant stock price fluctuations. 3. On August 13, whistleblowers were encouraged to provide non-public information to assist in the investigation of Capricor Therapeutics' violations, which could lead to further legal action and stock price volatility. The biotechnology industry has recently shown weak performance, with increased regulatory risks. Akanda rose 62.45% in pre-market trading. Based on recent key news: 1. On August 13, Akanda Corporation released the latest content, highlighting its market capitalization of approximately $2.71 million, with its stock price down 94.80% over the past 12 months, currently close to its annual low. This information may attract investor attention, leading to stock price fluctuations. Source: Newsfile 2. On August 14, Benzinga's technical analysis showed that Akanda's relative strength index was 29.27, indicating a negative stock price trend across all time frames. This analysis may affect market sentiment and drive stock price changes. Source: Benzinga 3. On August 14, FTF Company updated its passive leasing model for its 28 active cell tower sites, marking significant progress in its recurring revenue growth. This industry dynamic may indirectly impact Akanda's market performance. Source: Benzinga Market volatility is significant, and industry dynamics should be monitored ### Related Stocks - [BSX.US](https://longbridge.com/en/quote/BSX.US.md) - [FGI.US](https://longbridge.com/en/quote/FGI.US.md) - [WETO.US](https://longbridge.com/en/quote/WETO.US.md) - [CAPR.US](https://longbridge.com/en/quote/CAPR.US.md) - [AKAN.US](https://longbridge.com/en/quote/AKAN.US.md) ## Related News & Research - [How Investors Are Reacting To Boston Scientific (BSX) Recall Wave After Strong Mid‑Year Results](https://longbridge.com/en/news/295426841.md) - [Boston Scientific Corporation $BSX Shares Purchased by Fisher Funds Management LTD](https://longbridge.com/en/news/295764719.md) - [FGI Industries swings to Q2 profit on higher gross profit, lower costs](https://longbridge.com/en/news/295705856.md) - [Boston Scientific Q2 results beat estimates on cardiovascular strength](https://longbridge.com/en/news/294192730.md) - [Bessemer Group Inc. Sells 3,851,493 Shares of Boston Scientific Corporation $BSX](https://longbridge.com/en/news/293436694.md)